Ablynx Nv(ABLX)高管介绍_美股行情_同花顺金融网

来自 : stockpage.10jqka.com.cn/ABLX/m 发布时间：2021-03-25

自2011年4月以来，Bo Jesper Hansen，医学博士，哲学博士一直任公司董事。自2010年1月以来，他曾担任 Swedish Orphan Biovitrum AB董事会主席，这是一家瑞典的专业制药公司，专注于罕见疾病的医疗需求。此前，从1993年起，他曾在Swedish Orphan International AB 任多个职位。从1998年至2010年与Biovitrum的合并，他是公司的Swedish Orphan International Group 总裁兼首席执行官。在加盟Swedish Orphan International AB前，他在世界几个最大的制药公司担任医学顾问，包括Synthélabo, Pfizer, Inc., Pharmacia Corporation 和 Yamanouchi Pharmaceutical Co. Ltd.。他还创办了Scandinavian 医学研究公司。他是Topotarget A / S公司的董事局主席，是AblynxNV的董事和两家私营公司的董事。他获得了Copenhagen大学医学博士和哲学博士学位。

Bo Jesper Hansen has served as a member of our board of directors since 2013. Dr. Hansen currently serves as chairman of Laborie Inc., a position held since September 2016 and as non-executive director of Newron Pharmaceuticals SpA a position held since 2010 Orphazyme Aps, a position held since 2011 CMC AB, a position held since 2008 and Azanta A/S, a position held since 2016. He was executive chairman of Karolinska Development AB from 2013 until 2017. From January 2010 until May 2016 Dr. Hansen was the executive chairman of the board of Swedish Orphan Biovitrum AB, an international growth company specializing in the development, registration, marketing and distribution of pharmaceutical drugs for rare and life threatening diseases. Dr. Hansen held that position beginning in January 2010 as a result of the merger of Swedish Orphan International AB Group and Biovitrum. Prior to the merger, Dr. Hansen served in numerous positions with Swedish Orphan International AB Group, including as a co-founder and, from 1998 to 2010 chief executive officer, president and member of the board of directors. Dr. Hansen previously served on the board of Onxeo SA and as executive Chairman of TopoTarget A/S from 2010 until 2014 and on the board of Hyperion Therapeutics Inc. from 2011 until its acquisition by Horizon in 2015. He was also non-executive Director of Gambro from 2009 until its acquisition by Baxter in 2013 of Zymenex from 2008 until its acquisition by Chiesi in 2013 and of and Inspyr Therapeutics, Inc. from 2010 till 2017. Prior to this, Dr. Hansen founded Scandinavian Medical Research in 1991 and also served as Medical Advisor for Synth labo, Pfizer, Pharmacia and Yamanouchi Pharmaceutical. Dr. Hansen received his Doctor of Medicine degree and Ph.D. from the University of Copenhagen. 自2011年4月以来，Bo Jesper Hansen，医学博士，哲学博士一直任公司董事。自2010年1月以来，他曾担任 Swedish Orphan Biovitrum AB董事会主席，这是一家瑞典的专业制药公司，专注于罕见疾病的医疗需求。此前，从1993年起，他曾在Swedish Orphan International AB 任多个职位。从1998年至2010年与Biovitrum的合并，他是公司的Swedish Orphan International Group 总裁兼首席执行官。在加盟Swedish Orphan International AB前，他在世界几个最大的制药公司担任医学顾问，包括Synthélabo, Pfizer, Inc., Pharmacia Corporation 和 Yamanouchi Pharmaceutical Co. Ltd.。他还创办了Scandinavian 医学研究公司。他是Topotarget A / S公司的董事局主席，是AblynxNV的董事和两家私营公司的董事。他获得了Copenhagen大学医学博士和哲学博士学位。 Bo Jesper Hansen has served as a member of our board of directors since 2013. Dr. Hansen currently serves as chairman of Laborie Inc., a position held since September 2016 and as non-executive director of Newron Pharmaceuticals SpA a position held since 2010 Orphazyme Aps, a position held since 2011 CMC AB, a position held since 2008 and Azanta A/S, a position held since 2016. He was executive chairman of Karolinska Development AB from 2013 until 2017. From January 2010 until May 2016 Dr. Hansen was the executive chairman of the board of Swedish Orphan Biovitrum AB, an international growth company specializing in the development, registration, marketing and distribution of pharmaceutical drugs for rare and life threatening diseases. Dr. Hansen held that position beginning in January 2010 as a result of the merger of Swedish Orphan International AB Group and Biovitrum. Prior to the merger, Dr. Hansen served in numerous positions with Swedish Orphan International AB Group, including as a co-founder and, from 1998 to 2010 chief executive officer, president and member of the board of directors. Dr. Hansen previously served on the board of Onxeo SA and as executive Chairman of TopoTarget A/S from 2010 until 2014 and on the board of Hyperion Therapeutics Inc. from 2011 until its acquisition by Horizon in 2015. He was also non-executive Director of Gambro from 2009 until its acquisition by Baxter in 2013 of Zymenex from 2008 until its acquisition by Chiesi in 2013 and of and Inspyr Therapeutics, Inc. from 2010 till 2017. Prior to this, Dr. Hansen founded Scandinavian Medical Research in 1991 and also served as Medical Advisor for Synth labo, Pfizer, Pharmacia and Yamanouchi Pharmaceutical. Dr. Hansen received his Doctor of Medicine degree and Ph.D. from the University of Copenhagen.